Unilever acquires Sara Lee's personal-care business
This article was originally published in The Rose Sheet
Executive Summary
Consumer products firm announced Sept. 25 its $1.88 billion offer to purchase the global personal-care business of Sara Lee Corp. Sara Lee's global body-care portfolio includes products Sanex, Radox and Duschdas, and generates annual sales of more than $1 billion, according to the firm. "Personal care is a strategic category and a key growth driver for Unilever," says Unilever CEO Paul Polman. "This transaction builds on our portfolio in Western Europe and also in Asia. The Sara Lee brands enjoy strong consumer recognition, offer significant growth potential and are an excellent fit with Unilever's existing business." The transaction is expected to close in early 2010, according to Downers Grove, Ill.-based Sara Lee. "The divestiture of body care and European detergents would advance our strategy to concentrate on our core food and beverage business where we enjoy a strong competitive position and where we can generate superior shareholder returns," says Chairman and CEO Brenda C. Barnes. "We intend to use the proceeds from the divestiture to invest for growth in our core businesses and to repurchase stock.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.